Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Paradigm shift or shifting paradigm for type 1 diabetes.

Nakayama M, Eisenbarth GS.

Diabetes. 2012 May;61(5):976-8. doi: 10.2337/db12-0057. No abstract available.

2.

Prevention of type 1 diabetes in the rat with an allele-specific anti-T-cell receptor antibody: Vβ13 as a therapeutic target and biomarker.

Liu Z, Cort L, Eberwine R, Herrmann T, Leif JH, Greiner DL, Yahalom B, Blankenhorn EP, Mordes JP.

Diabetes. 2012 May;61(5):1160-8. doi: 10.2337/db11-0867. Epub 2012 Feb 24.

3.

Anti-alpha/beta T cell receptor monoclonal antibody provides an efficient therapy for autoimmune diabetes in nonobese diabetic (NOD) mice.

Sempé P, Bédossa P, Richard MF, Villà MC, Bach JF, Boitard C.

Eur J Immunol. 1991 May;21(5):1163-9.

PMID:
1828030
4.

Effect of T-cell receptor V beta-specific monoclonal antibodies on cyclophosphamide-induced diabetes mellitus in non-obese diabetic mice.

Taki T, Yokono K, Amano K, Hatamori N, Hirao Y, Tominaga Y, Maeda S, Kasuga M.

Diabetologia. 1993 May;36(5):391-6.

PMID:
8314442
6.

Administration of monoclonal antibodies against vascular cell adhesion molecule-1/very late antigen-4 abrogates predisposing autoimmune diabetes in NOD mice.

Tsukamoto K, Yokono K, Amano K, Nagata M, Yagi N, Tominaga Y, Moriyama H, Miki M, Okamoto N, Yoneda R, et al.

Cell Immunol. 1995 Oct 15;165(2):193-201.

PMID:
7553883
7.

Short-term administration of anti-L3T4 MoAb prevents diabetes in NOD mice.

Kurasawa K, Sakamoto A, Maeda T, Sumida T, Ito I, Tomioka H, Yoshida S, Koike T.

Clin Exp Immunol. 1993 Mar;91(3):376-80.

8.

Anti-T-cell receptor V beta antibodies in autoimmunity.

Acha-Orbea H.

Immunol Ser. 1993;59:193-202. Review. No abstract available.

PMID:
8461388
9.

Anti-TcR antibodies in autoimmune diseases.

Boitard C, Sempé P, Bach JF.

Immunol Ser. 1993;59:167-73. Review. No abstract available.

PMID:
8096399
10.

Selective elimination of alpha/beta T cells as a model for peripheral T-cell tolerance.

Dufter C, Terness P, Post S, Thies J, Otto G, Opelz G.

Transplant Proc. 1994 Dec;26(6):3233-4. No abstract available.

PMID:
7998127
11.

Establishment of T-cell lines from infiltrated NOD islets by stimulation of specific T-cell receptor V beta segments.

Maugendre D, Legrand B, Olivi M, Bedossa P, Bach JF, Carnaud C.

J Autoimmun. 1993 Aug;6(4):423-36.

PMID:
8105789
14.

Prevention of diabetes in BB/Wor rats treated with monoclonal antibodies to interferon-gamma.

Nicoletti F, Meroni PL, Landolfo S, Gariglio M, Guzzardi S, Barcellini W, Lunetta M, Mughini L, Zanussi C.

Lancet. 1990 Aug 4;336(8710):319. No abstract available.

PMID:
1974010
15.

Anti-GAD monoclonal antibody delays the onset of diabetes mellitus in NOD mice.

Menard V, Jacobs H, Jun HS, Yoon JW, Kim SW.

Pharm Res. 1999 Jul;16(7):1059-66.

PMID:
10450931
16.
17.

Can we change the course of beta-cell destruction in type 1 diabetes?

Gale EA.

N Engl J Med. 2002 May 30;346(22):1740-2. No abstract available.

PMID:
12037155
18.
19.
20.

HLA-DR*0401 expression in the NOD mice prevents the development of autoimmune diabetes by multiple alterations in the T-cell compartment.

Pow Sang L, Surls J, Mendoza M, Casares S, Brumeanu T.

Cell Immunol. 2015 Nov-Dec;298(1-2):54-65. doi: 10.1016/j.cellimm.2015.09.003. Epub 2015 Sep 7.

PMID:
26363521

Supplemental Content

Support Center